Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

Core Viewpoint - Kiniksa Pharmaceuticals, Ltd. (KNSA) shows significant upside potential with a mean price target of $35.86, indicating a 64.8$21.76 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $30 to$40, with a standard deviation of $4.18, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates a potential increase of 37.9%, while the highest suggests an 83.8% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [8] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding KNSA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 9.1%, with one estimate moving higher and no negative revisions [11] - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12]